MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses…
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,…
Q4 Net Revenues up 88% to $26.3 million vs. Q4 20222023 Net Revenues up 49% to $80.8 million vs. 2022Increases…
PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch…
STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment…
– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD…
Q4 Revenues of $28.2 millionQ4 Gross Margin of 58.0% (230 bps year-over-year improvement)Q4 operating income of $0.3 million, adjusted operating…
On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of…
– Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first…
Up to $3.5 M in cash proceedsUp to $4.5 M in debts conversion Proceeds to be used to further expand…